Immunotherapy Shows Promise in Treating Gliomas

Strategic Insights -

According to recent research published in the Journal of Neuropathology and Experimental Neurology, immunotherapy may offer an effective treatment for gliomas, a type of brain tumor that has been difficult to treat. The study found that intracerebral IL-12 can mediate rejection of glioma cells in a syngenic mouse model, and that this rejection is predominantly dependent on the presence of CD8+ T cells. Additionally, the researchers discovered that the rejection of tumors was independent of IFN-gamma, which contrasts with previous results obtained after in vitro or systemic stimulation with IL-12.

Key Takeaways:

  • Immunotherapy may be an effective treatment for gliomas, a type of brain tumor that has been difficult to treat.
  • Intracerebral IL-12 can mediate rejection of glioma cells in a syngenic mouse model.
  • The rejection of tumors was predominantly dependent on the presence of CD8+ T cells.
  • The rejection of tumors was independent of IFN-gamma.
  • The study's findings contrast with previous results obtained after in vitro or systemic stimulation with IL-12.
  • The University of Marburg, led by M. Vetter and colleagues, conducted the study.
  • The research was published in the Journal of Neuropathology and Experimental Neurology in 2009.

Statistics:

  • 68(5):525-534: The issue and page numbers of the study published in the Journal of Neuropathology and Experimental Neurology.
  • 2009: The year the study was published.
  • 530 Walnut St., Philadelphia, PA 19106-3621, USA: The address of the publisher of the Journal of Neuropathology and Experimental Neurology, Lippincott Williams & Wilkins.
  • CD8+ T cells: The type of immune cell predominantly responsible for the rejection of tumors.
  • IFN-gamma: The interferon that was shown to be independent of tumor rejection.

Sources:

  • Vetter, M., et al. "Intracerebral Interleukin 12 Induces Glioma Rejection in the Brain Predominantly by CD8(+) T Cells and Independently of Interferon-gamma." Journal of Neuropathology and Experimental Neurology, vol. 68, no. 5, 2009, pp. 525-534.
  • University of Marburg, Dept. of Neuropathology, Baldingerstr, D-35039 Marburg, Germany.
  • Lippincott Williams & Wilkins, publisher of the Journal of Neuropathology and Experimental Neurology.